AbbVie, a leading global, research and development-based biopharmaceutical company acquires Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. Financial terms were not disclosed. "AbbVie has built a leadership position in oncology and their world-class capabilities will enable the accelerated development of our pipeline of STING modulators," Michael Gallatin, Mavupharma Co-Founder.